Mesoblast Limited income statement MESO
In fiscal 2025, which ended Jun 30, 2025, Mesoblast Limited reported revenue of $17.2 million, up 191.4% from the year before. It recorded a net loss of $102.1 million. Diluted earnings per share were -$0.08. Across the 8 fiscal years shown, revenue shrank from $17.3 million in fiscal 2018 to $17.2 million in fiscal 2025, about 0.1% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2025
Jun 30, 2025
|
FY 2024
Jun 30, 2024
|
FY 2023
Jun 30, 2023
|
FY 2022
Jun 30, 2022
|
FY 2021
Jun 30, 2021
|
FY 2020
Jun 30, 2020
|
FY 2019
Jun 30, 2019
|
FY 2018
Jun 30, 2018
|
|---|---|---|---|---|---|---|---|---|
| Revenue |
17
+191.4%
|
6
-21.3%
|
8
-26.5%
|
10
+37.4%
|
7
-76.9%
|
32
+92.3%
|
17
-3.6%
|
17
|
| Cost of revenue |
5
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Gross profit |
12
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Research and development |
35
-12.4%
|
40
-24.8%
|
53
+61.0%
|
33
-38.1%
|
53
-5.7%
|
56
-6.1%
|
60
-9.3%
|
66
|
| Selling, general and administrative |
39
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Pretax income |
-102
-15.5%
|
-88
-7.4%
|
-82
+10.4%
|
-92
+8.1%
|
-100
-14.1%
|
-87
+11.5%
|
-99
-49.7%
|
-66
|
| Income tax |
0
+272.8%
|
-0
+9.9%
|
-0
+11.3%
|
-0
+70.8%
|
-1
+91.3%
|
-9
-5.1%
|
-9
+70.8%
|
-31
|
| Net income |
-102
-16.1%
|
-88
-7.4%
|
-82
+10.4%
|
-91
+7.6%
|
-99
-26.8%
|
-78
+13.2%
|
-90
-154.5%
|
-35
|
| Basic EPS |
-0.08
+5.1%
|
-0.09
+15.4%
|
-0.11
+21.3%
|
-0.13
+18.1%
|
-0.16
-10.8%
|
-0.15
+18.8%
|
-0.18
-139.6%
|
-0.08
|
| Diluted EPS |
-0.08
+5.1%
|
-0.09
+15.4%
|
-0.11
+21.3%
|
-0.13
+18.1%
|
-0.16
-10.8%
|
-0.15
+18.8%
|
-0.18
-139.6%
|
-0.08
|
| Weighted average shares, basic |
1,208
+22.4%
|
987
+26.9%
|
778
+13.9%
|
683
+12.9%
|
605
+14.4%
|
529
+7.0%
|
494
+6.2%
|
466
|
| Weighted average shares, diluted |
1,208
+22.4%
|
987
+26.9%
|
778
+13.9%
|
683
+12.9%
|
605
+14.4%
|
529
+7.0%
|
494
+6.2%
|
466
|
| Other measures | ||||||||
| Depreciation and amortization |
2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Margins | ||||||||
| Gross margin |
70.17%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Pretax margin |
-592.00%
|
-1,493.51%
|
-1,094.53%
|
-896.93%
|
-1,340.19%
|
-271.66%
|
-590.56%
|
-380.47%
|
| Profit margin |
-593.92%
|
-1,490.27%
|
-1,091.71%
|
-894.59%
|
-1,329.18%
|
-242.38%
|
-537.01%
|
-203.51%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- MESO (Nasdaq), MEOBF (OTC)
- Fiscal year ends
- June 30
- Incorporated in
- Australia
- Headquarters
- Melbourne, Victoria, Australia
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1345099
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.